Atara Biotherape SEC Filings

Yanina Grant-Huerta, Chief Accounting Officer and Director of Atara Biotherapeutics (ATRA), reported automatic share sales on August 18, 2025 to satisfy tax withholding obligations tied to the vesting of previously granted restricted stock units. The filing lists three automatic dispositions executed via broker at weighted-average prices of approximately $11.61 per share, resulting in reported beneficial ownership of 35,258 shares after the transactions. The sales were executed pursuant to a sale-to-cover provision in the award agreement and the report was signed by an attorney-in-fact on August 20, 2025.

Panacea Innovation Ltd, a reporting person linked to Atara Biotherapeutics, Inc. (ATRA), acquired 55,000 shares of Atara common stock on 08/15/2025 at a weighted-average price of $12.1895 per share. After the transaction, the reporting persons disclose beneficial ownership of 1,405,000 shares held indirectly. The filing identifies Panacea Innovation Limited and James Huang (who is the sole owner of Panacea Innovation Limited) as reporting persons and explains that Panacea entities hold securities through Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P.; the filing also includes a disclaimer that the reporting persons may be deemed to share beneficial ownership but disclaim such ownership. The price reported is a weighted average of multiple purchases ranging from $11.83 to $12.44.

Amendment No. 1 to a Schedule 13D reports that a group of Panacea-related entities and James Huang together beneficially own 1,712,900 shares of Atara Biotherapeutics common stock, representing 20.0% of the 7,023,032 shares outstanding as of August 6, 2025. The position includes 307,900 warrants that are immediately exercisable but are subject to a contractual cap preventing exercise to the extent it would increase beneficial ownership above 19.99%, so the warrants cannot currently be exercised. Panacea Venture Healthcare Fund II, L.P. purchased 74,335 shares in open market transactions from July 17 through August 19, 2025 for approximately $857,000, including 19,335 shares at a weighted average $9.6391 and 55,000 shares at a weighted average $12.1895. The filing discloses the ownership chain: James Huang owns Panacea Innovation Limited, which controls the GP entities and the funds. No legal proceedings are reported.

Form 144 notice for Atara Biotherapeutics (ATRA) shows a proposed sale of 3,346 shares of common stock on 08/18/2025 through Morgan Stanley Smith Barney (Executive Services, Sandy, UT), with an aggregate market value of $41,122.34. The shares were acquired as the settlement of vested RSUs issued under an S-8 registration on 08/15/2025; 7,788 shares were received in that settlement and payment was recorded as equity compensation for services rendered. The filer disclosed a prior sale on 05/16/2025 of 3,276 shares for gross proceeds of $22,155.59. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.

Atara Biotherapeutics (ATRA) filed a Form 144 reporting a proposed sale of 2,048 shares of common stock on or about 08/18/2025 through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $25,169.92. The filing shows those shares were acquired on 08/15/2025 as settlement of vested restricted stock units issued under an S-8 registration plan, with payment noted as equity compensation for services rendered. The filer also reported a prior sale on 05/16/2025 of 2,218 shares for gross proceeds of $15,000.33. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.

Atara Biotherapeutics (ATRA) reported a pronounced change in its mid‑2025 financial position driven by transactions with Pierre Fabre and cost reductions. Total assets declined to $36.9 million at June 30, 2025 from $109.1 million at year‑end, and cash and cash equivalents were $16.9 million. Total liabilities fell to $71.9 million, and stockholders’ deficit improved to $(35.0) million.

Commercialization revenue for the six months ended June 30, 2025 was $115.7 million, reflecting recognition of deferred revenue tied to the transfer of manufacturing, inventory and related services to Pierre Fabre; deferred revenue declined from $95.1 million at year‑end to $1.6 million at June 30. Net income for the six months was $40.4 million versus a loss of $50.8 million a year earlier, producing basic earnings per share of $3.52 for the period. The company recorded restructuring charges of $11.3 million and a lease right‑of‑use impairment of $4.1 million. Management discloses substantial doubt about the company’s ability to continue as a going concern and plans to seek additional capital.

Atara Biotherapeutics reported that it announced financial results for the second quarter ended June 30, 2025 and furnished a press release as Exhibit 99.1 to its Form 8-K. The filing specifies the press release is being furnished (not "filed") and therefore is not subject to the liabilities of Sections 11 and 12(a)(2) of the Securities Act or deemed "filed" under Section 18 of the Exchange Act, and will not be incorporated by reference into other SEC filings unless expressly referenced. The Form lists the company ticker as ATRA and is signed by the Chief Accounting Officer.